Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases Åslaug Helland, MD, PhD, Steinar Solberg,

Slides:

Advertisements

Similar presentations

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Advertisements

Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD

Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

EGFR Gene Alterations in a Norwegian Cohort of Lung Cancer Patients Selected for Surgery Åslaug Helland, MD, PhD, Hege Marian Skaug, MSc, Lilach Kleinberg,

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Two Classic Lyrics Joined by a Contemporary Tune—Environmental Pro-Carcinogen Exposure and Genetic Susceptibility in Lung Cancer Risk Ping Yang, MD,

Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma Dean A. Fennell, PhD, FRCP,

Impact of Race on Outcomes of Patients with Non-small Cell Lung Cancer

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

National Cancer Database Report on Pneumonectomy Versus Lung-Sparing Surgery for Malignant Pleural Mesothelioma Vivek Verma, MD, Christopher A. Ahern,

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma

Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG.

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review Swati Kulkarni, MD, Emily T. Vella,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Increasing Age and Carcinoma Not Otherwise Specified: A 20-Year Population Study of 40,118 Lung Cancer Patients Camilla Maria T. Sagerup, MD, Milada.

Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119 Wallace Akerley, MD, Jason McCoy, MS, Paul J.

DNA Repair Polymorphisms and Treatment Outcomes of Patients with Malignant Mesothelioma Treated with Gemcitabine-Platinum Combination Chemotherapy Nina.

Electronic Updates for JTO Readers

Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients Hes A.P. Brokx, MD, Otto Visser, MD, PhD,

John E. Pilling, FRCS (CTh), Michael E

Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer Daniel Morgensztern, MD, Saiama.

Patient-Reported Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer Frank J. Lagerwaard, MD, PhD, Neil K. Aaronson,

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Improved Overall Survival with Aggressive Primary Tumor Radiotherapy for Patients with Metastatic Esophageal Cancer David M. Guttmann, MD, MTR, Nandita.

Treatment Modalities for T1N0 Esophageal Cancers: A Comparative Analysis of Local Therapy Versus Surgical Resection Mark F. Berry, MD, Josiane Zeyer-Brunner,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Standard Outcome Measures for Thymic Malignancies

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Erratum Journal of Thoracic Oncology

Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaive, Advanced, Non- small Cell Lung Cancer Patients Aged 70 Years or Older Yuh-Min Chen,

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Characteristics of Thoracic Malignancies That Occur After Solid-Organ Transplantation Caroline Génébès, MD, Laurent Brouchet, MD, PhD, Nassim Kamar, MD,

Disease Control as a Predictor of Survival with Gefitinib and Docetaxel in a Phase III Study (V-15-32) in Advanced Non-small Cell Lung Cancer Patients

Treatment of Malignant Pleural Mesothelioma with Carboplatin, Liposomized Doxorubicin, and Gemcitabine: A Phase II Study Gunnar Hillerdal, MD, PhD, Jens.

Phase II Study of Bendamustine in Relapsed Chemotherapy Sensitive or Resistant Small-Cell Lung Cancer Philip E. Lammers, MD, Yu Shyr, PhD, Chung-I Li,

Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded.

Impact of a Multidisciplinary Thoracic Oncology Clinic on the Timeliness of Care Richard F. Riedel, MD, Xiaofei Wang, PhD, Meg McCormack, PA-C, Eric Toloza,

A Phase 2 Randomized Trial of Paclitaxel and Carboplatin with or without Panitumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients Hideki Endoh, MD, PhD,

Associations between TS, TTF-1, FR-α, FPGS, and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Pemetrexed Plus Carboplatin.

Conditional Survival of Malignant Thymoma Using National Population-Based Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2011) Ellen.

Pleurectomy/Decortication is Superior to Extrapleural Pneumonectomy in the Multimodality Management of Patients with Malignant Pleural Mesothelioma Loïc.

Should Never-Smokers at Increased Risk for Lung Cancer Be Screened?

International Thymic Malignancies Interest Group: A Way Forward

Prospective Assessment of Continuation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition.

Linda L. Garland, MD, Kari Chansky, MS, Antoinette J

European Lung Cancer Conference (ELCC) 2016 Organisation

Prognostic Significance of CT-Determined Sarcopenia in Patients with Small-Cell Lung Cancer Eun Young Kim, MD, Young Saing Kim, MD, Inkeun Park, MD,

Pleural Metastases of Malignant Melanoma

Reduced Folate Carrier and Folylpolyglutamate Synthetase, but not Thymidylate Synthase Predict Survival in Pemetrexed-Treated Patients Suffering from.

David James Pinato, MD, MRes, Francesco A

Palmar Bullous Blistering Induced by Erlotinib

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Epidemiology of Thymoma and Associated Malignancies

Debby P. M. van den Bogaert, MD, Ellen M

A Review of First-Line Treatment for Small-cell Lung Cancer

Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD

Presentation transcript:

Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases Åslaug Helland, MD, PhD, Steinar Solberg, MD, PhD, Odd Terje Brustugun, MD, PhD Journal of Thoracic Oncology Volume 7, Issue 12, Pages 1858-1861 (December 2012) DOI: 10.1097/JTO.0b013e318275b346 Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Absolute (upper panel) and age-adjusted (lower panel) increase of mesothelioma incidence in Norway for men (blue line) and women (red line) from 1970 to 2009. Journal of Thoracic Oncology 2012 7, 1858-1861DOI: (10.1097/JTO.0b013e318275b346) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 The antimetabolite pemetrexed was not used in Norway before 2003; the first patient was treated in February 2003, and during the first 2 years 65 patients received this treatment. Journal of Thoracic Oncology 2012 7, 1858-1861DOI: (10.1097/JTO.0b013e318275b346) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Survival for 1 year and 3 years for women (upper panel) and men (lower panel) over the last 40 years. OS, overall survival. Journal of Thoracic Oncology 2012 7, 1858-1861DOI: (10.1097/JTO.0b013e318275b346) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Median survival for men diagnosed with malignant mesothelioma from 1970 to 2009. Ninety-five percent confidence intervals are shown. Journal of Thoracic Oncology 2012 7, 1858-1861DOI: (10.1097/JTO.0b013e318275b346) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions